Lung Cancer Trials Ask AI to find trials
UnknownNot applicableNCT03878537
Official study title

Recurrence Monitoring in NSCLC Using Circulating Tumor DNA

Study summary

This research study is investigating the role of cell free tumor DNA profiling in determining disease relapse and/or progression for patients with advanced NSCLC.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Recurrent or relapsed

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 23, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Unknown

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Scripps Translational Science Institute

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Scripps Translational Science Institute
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Recurrent or relapsed→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Treatment naïve biopsy confirmed not surgically resectable stage III or greater NSCLC
  • Baseline CT imaging available
Reasons someone may not be able to joinExclusion criteria
  • Patients unable to undergo biopsy for initial tissue diagnosis
  • Patients who do not wish to pursue standard of care therapy
  • Patients with another diagnosis of malignancy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Scripps Health/Scripps Clinic Hillcrest/Scripps Clinic Torrey PinesSan Diego, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 23, 2021. Always confirm current availability with the study team.

View original record ↗